retatrutide nonalcoholic steatohepatitis trial Results from a new efficacy and safety analysis of the REGENERATE of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic retatrutide nonalcoholic steatohepatitis nash trial

Fund Details Issuer Roundhill Investments Fund Name Roundhill GLP-1 & Weight Loss ETF Tax Classification Regulated Investment Company Stock Exchange NASDAQ Current Symbol NASDAQ:OZEM Inception Date 5/20/2024 Fund Manager Will Hershey, Tim Maloney, Dave Mazza, Drew Walsh Previous Symbol NASDAQ:OZEM Web N/A Phone N/A Fund Focus Asset Class Equity Benchmark N/A Category Strategy Focus Theme Development Level Blended Development Region Global Number of Holdings 53 Fund Statistics Assets Under Management $0.00 Average Daily Volume $0.00 Discount/Premium 0.00% Administrator, Advisor and Custodian Administrator U.S

You're being active

Stick with refrigerator storage and make a fresh batch weekly

Any future use would depend on licensing and regulatory approval in the UK

Do not freeze reconstituted retatrutide

The risk of hepatocellular carcinoma (liver cancer) falls markedly